Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Smart_Money who wrote (99050)	9/23/1999 12:34:00 PM
From: blackmerlin	Read Replies (2) \| Respond to of 119973

NEOT Alzheimer Drug in Phase 2 FDA Trials. Good Progress. A strong buy here. "Thursday September 23, 9:30 am Eastern Time Company Press Release SOURCE: NeoTherapeutics, Inc. NeoTherapeutics Announces Clinical Trial to Study the Brain Effects of NEOTROFIN in Alzheimer's Disease IRVINE, Calif., Sept. 23 /PRNewswire/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT - news, NEOTW - news) announced today it is conducting a Phase 2 clinical trial to study the effects of NEOTROFIN(TM) directly in the brain. NeoTherapeutics has initiated this study of NEOTROFIN(TM) (AIT-082, leteprinim potassium) in a limited number of patients with mild to moderate Alzheimer's disease at the University of California, Irvine. This study is being conducted by Dr. Steven Potkin and colleagues at the UC Irvine Brain Imaging Center, and is designed to use modern brain imaging techniques such as MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) to measure changes seen in the brain during and after NEOTROFIN(TM) therapy. Each patient will be involved in the treatment and evaluation phases of the study for six weeks. ``Our clinic has previously shown that PET imaging can detect brain deficits associated with Alzheimer's disease,' said Dr. Potkin. ``We are excited to be able to evaluate whether the unique beneficial action demonstrated by NEOTROFIN(TM) can be seen during the treatment of patients with Alzheimer's disease.' ``NeoTherapeutics is pleased to be working with a physician of Dr. Potkin's reputation on this exciting project,' said Michelle S. Glasky, Ph.D., Vice President, Scientific Affairs of NeoTherapeutics. ``Positron Emission Tomography brain scans from Alzheimer's patients undergoing NEOTROFIN(TM) therapy will broaden our understanding of how this novel drug affects the brain.' NEOTROFIN(TM) is NeoTherapeutics' lead compound and is being developed for nerve repair and regeneration, with Alzheimer's disease as its first clinical indication. Pre-clinical studies have demonstrated that NEOTROFIN(TM) can control the production of multiple natural neurotrophic factors and restore function in animal models of cognitive decline, aging, brain injury and spinal cord injury. Results obtained from the five completed Phase 1 clinical trials and the recently completed Phase 2a trial in patients with mild to moderate Alzheimer's disease indicate that NEOTROFIN(TM) can be orally administered, is well tolerated and produces positive effects on memory and behavioral function in humans. NeoTherapeutics' research program is focused on designing and developing small molecules capable of promoting nerve regeneration and repair for a range of neurological diseases and conditions such as Alzheimer's and Parkinson's diseases, stroke and spinal cord injury. Additional compounds in NeoTherapeutics' product pipeline address other health issues such as migraine and depression. For additional Company information, visit the NeoTherapeutics web site at www.neotherapeutics.com. This press release contains forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission. Contact: Investment Community: Carol Gruetter of NeoTherapeutics, Inc., 949-788-6700 ext. 236, cgruetter@neotherapeutics.com; or Media: Kelly Finley of Halsted Communications, Inc., 800-600-7111 ext. 250, 323-225-1835, kfinley@halsted.com, for NeoTherapeutics, Inc. SOURCE: NeoTherapeutics, Inc." Regards, Good Luck, Jake Blackmerlin